Kyverna's Miv-cel Shows Deep B-Cell Depletion in Rheumatoid Arthritis Trial
Event summary
- Kyverna Therapeutics presented updated Phase 1 data for miv-cel at EULAR 2026, showing 66.6% of patients met ACR70 response by Week 36.
- Single-dose miv-cel achieved deep B-cell depletion and immune reset in ACPA-positive, treatment-refractory rheumatoid arthritis patients.
- Phase 2 of the COMPARE trial comparing miv-cel to rituximab is fully enrolled.
- Miv-cel demonstrated a well-tolerated safety profile with no high-grade cytokine release syndrome or neurotoxicity.
The big picture
Kyverna's updated data positions miv-cel as a potential paradigm shift in treating refractory autoimmune diseases, particularly where current biologics fail. The Phase 1 results suggest a durable immune reset could address unmet needs in ACPA-positive rheumatoid arthritis and potentially other B-cell-driven conditions. The company's pipeline expansion into neuroimmunology further underscores its strategy to dominate the cell therapy space for autoimmune indications.
What we're watching
- Clinical Efficacy
- Whether miv-cel's deep B-cell depletion and immune reset can translate into durable remission across multiple autoimmune diseases.
- Regulatory Pathway
- The pace at which Kyverna advances its rolling BLA submission for stiff person syndrome and plans for other indications.
- Competitive Positioning
- How miv-cel's differentiated profile compares to existing therapies like rituximab in the treatment-refractory RA market.
Related topics